Teva Pharmaceutical Industries, Ltd.: Neoplasms trials
The registry lists 13 Neoplasms studies with Teva Pharmaceutical Industries, Ltd. as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 7Phase 2 6Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsTerminatedNCT04157517Phase 1/2Results posted
- Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01348919Phase 1/2Results posted
- Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid TumorsTerminatedNCT01311713Phase 1/2Results posted
- Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other AgentsTerminatedNCT00825227Phase 2Results posted
- Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and TolerabilityCompletedNCT01400854
- Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell LymphomaCompletedNCT01345357Phase 1
- Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid TumorsCompletedNCT00920595Phase 1
- Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced CancerCompletedNCT00875264Phase 1
- Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory MalignancyCompletedNCT00863850Phase 1
- Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough PainCompletedNCT00236093Phase 2
- Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)CompletedNCT00236041Phase 2
- OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer PatientsCompletedNCT00105937Phase 3
- Treatment of Breakthrough Pain in Opioid Tolerant Cancer PatientsCompletedNCT00105287Phase 3